JAAD study examines disparities in infantile hemangioma care

A retrospective cohort study published in the Journal of the American Academy of Dermatology, Volume 95, Issue 5, in November 2026 measures how area deprivation, race, and ethnicity shape the care infants with hemangiomas receive.

The study, titled "Disparities in care of infantile hemangiomas: A retrospective cohort study measuring the impact of area deprivation, race, and ethnicity," was authored by Sarah E. Servattalab, Katherine Barahona Paz, Shannon McLaughlin, Alexandra Epee-Bounya, Jennifer T. Huang, and Pierre-Olivier Grenier.

Infantile hemangiomas are the most common vascular tumors of infancy, and the paper's design speaks directly to a question dermatologists ask often: who gets timely, appropriate treatment, and who does not?

What does the study measure?

The authors built their analysis on a retrospective cohort, a design that looks backward at documented care rather than randomizing patients prospectively. That structure lets them compare real-world practice patterns across patient groups rather than idealized trial conditions.

The exposure variables sit at two levels. Individual-level measures cover race and ethnicity. Neighborhood-level measures draw on area deprivation, an index that aggregates socioeconomic conditions by geography rather than by single household.

The outcome of interest is care received for infantile hemangiomas. The study's title frames this plainly: the authors are measuring impact, not merely describing differences.

Why does this matter for dermatology practice?

Disparity research in pediatric dermatology has gained urgency as payers and health systems push screening equity into quality metrics. Infantile hemangiomas carry a treatment window that rewards early recognition, and delayed referral can change outcomes for lesions near eyes, airways, or other high-risk sites.

By pairing area deprivation with race and ethnicity in one model, the study design lets clinicians see whether neighborhood disadvantage tracks with care independent of individual demographics — or whether the two move together. That distinction matters for intervention design.

The publication lands in JAAD, Volume 95, Issue 5, dated November 2026, placing it in the journal's peer-reviewed original-investigation stream rather than a commentary or review format.

What comes next?

For dermatologists reading the full paper, the actionable pieces will be the cohort's size and composition, the magnitude of the gaps the authors quantify, and any referral-timing findings that map onto existing hemangioma management pathways. The study's framework — deprivation indices paired with race and ethnicity — offers a template other pediatric dermatology groups could apply to their own catchment data.